{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T23:15:22Z","timestamp":1789773322761,"version":"4.0.1"},"reference-count":242,"publisher":"Informa UK Limited","issue":"11","funder":[{"name":"Science and Engineering Research Board (SERB), Department of Science and Technology, Government of India","award":["CRG\/2022\/003884"],"award-info":[{"award-number":["CRG\/2022\/003884"]}]}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Opinion on Therapeutic Patents"],"published-print":{"date-parts":[[2025,11,2]]},"DOI":"10.1080\/13543776.2025.2556819","type":"journal-article","created":{"date-parts":[[2025,9,5]],"date-time":"2025-09-05T15:39:55Z","timestamp":1757086795000},"page":"1099-1139","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":5,"title":["Toll-like receptor agonists as cancer therapeutics: a patent review (2014\u20132024)"],"prefix":"10.1080","volume":"35","author":[{"given":"Pankaj","family":"Kumar","sequence":"first","affiliation":[{"name":"Panjab University","place":["Chandigarh, India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zahid Bashir","family":"Zargar","sequence":"additional","affiliation":[{"name":"Panjab University","place":["Chandigarh, India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kanwaljit","family":"Chopra","sequence":"additional","affiliation":[{"name":"Panjab University","place":["Chandigarh, India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4886-1435","authenticated-orcid":false,"given":"Sandip V.","family":"Pawar","sequence":"additional","affiliation":[{"name":"Panjab University","place":["Chandigarh, India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1241-9146","authenticated-orcid":false,"given":"Deepak B.","family":"Salunke","sequence":"additional","affiliation":[{"name":"Panjab University","place":["Chandigarh, India"]},{"name":"National Institute of Pharmaceutical Education and Research","place":["Mohali, India"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2025,9,18]]},"reference":[{"key":"e_1_3_5_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2024.03.004"},{"key":"e_1_3_5_4_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2014.00461"},{"key":"e_1_3_5_5_1","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.00102"},{"key":"e_1_3_5_6_1","doi-asserted-by":"publisher","DOI":"10.3390\/cells10061374"},{"key":"e_1_3_5_7_1","doi-asserted-by":"publisher","DOI":"10.1124\/pr.109.001073"},{"key":"e_1_3_5_8_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11882-011-0234-3"},{"key":"e_1_3_5_9_1","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.989664"},{"key":"e_1_3_5_10_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22041560"},{"key":"e_1_3_5_11_1","volume-title":"Potential value of pharmacological agents acting on toll-like receptor (TLR) 7 and\/or TLR8 in COVID-19. Current research in pharmacology and drug discovery","author":"Khalifa AE","year":"2021","unstructured":"Khalifa AE, Ghoneim AI. Potential value of pharmacological agents acting on toll-like receptor (TLR) 7 and\/or TLR8 in COVID-19. Current research in pharmacology and drug discovery. Elsevier B.V.; 2021."},{"key":"e_1_3_5_12_1","doi-asserted-by":"publisher","DOI":"10.3390\/jcm11216356"},{"key":"e_1_3_5_13_1","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics15041143"},{"key":"e_1_3_5_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.medidd.2022.100122"},{"key":"e_1_3_5_15_1","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-002758"},{"key":"e_1_3_5_16_1","doi-asserted-by":"publisher","DOI":"10.1038\/mi.2014.93"},{"key":"e_1_3_5_17_1","unstructured":"Kingston M Aisling D. Toll-like receptor 2 agonists and vaccines and uses thereof. WO2015\/140234A1. 2015."},{"key":"e_1_3_5_18_1","unstructured":"Ting Jenny P-Y Willie June B Hao G et al. Methods and treatments using toll-like receptor agonists to mitigate hematopoietic myeloid loss increase gastrointestinal recovery and reduce tumor growth. Wo2019\/099967Al. 2019."},{"key":"e_1_3_5_19_1","unstructured":"Jessica Baker F Marie L-E Pamela M C-R et al. Treatment methods. Wo2020\/069454al. 2020."},{"key":"e_1_3_5_20_1","unstructured":"Chelsi Danielle C Ramnik X. Immunomodulatory lipids and uses thereof. WO2023\/141470A2. 2023."},{"key":"e_1_3_5_21_1","unstructured":"Scoville Craig D. Immunologically active polypeptide. WO2024\/006746Al. 2024."},{"key":"e_1_3_5_22_1","doi-asserted-by":"publisher","DOI":"10.34172\/bi.2022.23896"},{"key":"e_1_3_5_23_1","doi-asserted-by":"publisher","DOI":"10.1038\/cmi.2013.59"},{"key":"e_1_3_5_24_1","doi-asserted-by":"publisher","DOI":"10.1021\/jm301694x"},{"key":"e_1_3_5_25_1","unstructured":"Carson Dennis A Cottam Howard B Tomoko H et al. Compositions and methods for modulating TLR4. Wo2014\/052828al. 2014."},{"key":"e_1_3_5_26_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-024-03679-5"},{"key":"e_1_3_5_27_1","doi-asserted-by":"publisher","DOI":"10.3892\/ijmm.2022.5206"},{"key":"e_1_3_5_28_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15102752"},{"key":"e_1_3_5_29_1","unstructured":"Anatoli G Lyudmila B Andrei G. Use of toll-like receptor agonist for treating cancer. US20140248260A1. 2014."},{"key":"e_1_3_5_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2024.07.020"},{"key":"e_1_3_5_31_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.812774"},{"key":"e_1_3_5_32_1","unstructured":"Gudkov A Natarajan V. Compositions and methods using toll-like receptor 5 and toll-like receptor agonist. Wo2014\/098649al. 2014."},{"key":"e_1_3_5_33_1","doi-asserted-by":"publisher","DOI":"10.1186\/s40364-022-00436-7"},{"key":"e_1_3_5_34_1","doi-asserted-by":"publisher","DOI":"10.3892\/mco.2024.2799"},{"key":"e_1_3_5_35_1","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.00046-08"},{"key":"e_1_3_5_36_1","unstructured":"Alex C Timothy H Yongkai L et al. Compounds and compositions as toll-like receptor 7 agonists. Wo2015\/168279al. 2015."},{"key":"e_1_3_5_37_1","unstructured":"Christophe H. Substituted imidazoquinolines. Wo2019\/048036al. 2019."},{"key":"e_1_3_5_38_1","unstructured":"Christophe H. Substituted imidazoquinolines. Wo2019\/048350al Henry Christophe. 2019."},{"key":"e_1_3_5_39_1","unstructured":"Thomas P Carola Shen Hong Yun Hongying R Sabine H et al. 7-substituted sulfonimidoylpurinone compounds and derivatives for the treatment and prophylaxis of liver cancer. Wo2019\/166432Al. 2019."},{"key":"e_1_3_5_40_1","unstructured":"Poeschinger T Ries C Shen H et al. 7-substituted sulfonimidoylpurinone compounds and derivatives for the treatment and prophylaxis of liver cancer. Us2020\/0268762al. 2020."},{"key":"e_1_3_5_41_1","unstructured":"Sean Wesley S Craig Alan C. Antibody conjugates of toll-like receptor agonists. Wo 2020\/056192 al. 2020."},{"key":"e_1_3_5_42_1","unstructured":"Alice Y Andreas M Cristina A et al. Immunomodulator antibody drug conjugates and uses thereof. Wo2020\/252015al. 2020."},{"key":"e_1_3_5_43_1","unstructured":"Webber Stephen E Appleman James R. TLR7 agonists. Us2021\/0155652al. 2021."},{"key":"e_1_3_5_44_1","unstructured":"Matthew C Liqi H Sanjeev G et al. lH-pyrazolo[4 3-d]pyrimidine compounds as toll-like receptor 7 (TLR7) agonists. Wo2021\/154662al. 2021."},{"key":"e_1_3_5_45_1","unstructured":"Sjoerd Henricus VDB Ziena A Vos Van Steenwijk Peggy Jacqueline D. Biomarker for predicting the response to TLR 7-agonist immunotherapy of squamous intraepithelial lesions and therapeutic use thereof. Wo2023\/222710al. 2023."},{"key":"e_1_3_5_46_1","unstructured":"Graham Albert Edwin G Truman H-S Brant Michael G et al. Immunomodulator purine-derived compounds conjugates thereof and methods of use thereof. WO2024\/020684Al. 2024."},{"key":"e_1_3_5_47_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12935-022-02708-6"},{"key":"e_1_3_5_48_1","unstructured":"Valerie O Peter B Sean Wesley S et al. Compositions for the treatment of disease with immune stimulatory conjugates. Wo2020\/056008al. 2020."},{"key":"e_1_3_5_49_1","unstructured":"Ninghui Y. Imidazoquinoline amine derivatives pharmaceutical composition use thereof. Wo2020\/160054al. 2020."},{"key":"e_1_3_5_50_1","unstructured":"Sung-Ju M Mingchao K Nickolas K et al. Compositions containing methods and uses of antibody-TLR agonist conjugates. Wo2020\/168017al. 2020."},{"key":"e_1_3_5_51_1","unstructured":"Shelley Erin A Alonso Michael N David D et al. Macromolecule-supported TLR agonists. Wo2020\/190762al. 2020."},{"key":"e_1_3_5_52_1","unstructured":"Griesgraber George W Cohen Hannah C Devon M H-D et al. Phenethyl substituted imidazo [4 5-c]quinoline compounds with ann-1 branched group. Wo2020\/250089al. 2020."},{"key":"e_1_3_5_53_1","unstructured":"Omar A Andrew F Ethan Lawrence F et al. Imidazo[4 5-c]pyridine derivatives as toll-like receptor agonists. Wo2021\/009676Al. 2021."},{"key":"e_1_3_5_54_1","unstructured":"Yu-Cheng C. 4-amino-imidazoquinoline compounds and use thereof. Wo2021\/086689al. 2021."},{"key":"e_1_3_5_55_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.addr.2021.05.013"},{"key":"e_1_3_5_56_1","unstructured":"Lixin L. Andtbacka Robert Huang Tao. Cancer treatment with TLR agonist. Wo2022\/047083Al. 2022."},{"key":"e_1_3_5_57_1","unstructured":"Fanton Christie P Haglund Cathleen M Jonathan Z. Tlr agonist compounds and related cancer immunotherapy methods. Wo2022\/098954al. 2022."},{"key":"e_1_3_5_58_1","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines10050819"},{"key":"e_1_3_5_59_1","unstructured":"Helene B-L. Toll-like receptor agonist. Wo2022\/125791al. 2022."},{"key":"e_1_3_5_60_1","unstructured":"Lianyong C Yong Z. Conjugate comprising toll-like receptor agonist. Wo2023\/198195al. 2023."},{"key":"e_1_3_5_61_1","unstructured":"Ho Young S Sang Eun C Won Mi L et al. Imidazo[4 5-c]pyridine derivative compounds as TLR7\/8 modulators. Wo2023\/209441al. 2023."},{"key":"e_1_3_5_62_1","doi-asserted-by":"publisher","DOI":"10.1038\/cmi.2012.38"},{"key":"e_1_3_5_63_1","doi-asserted-by":"publisher","DOI":"10.15252\/emmm.201403918"},{"key":"e_1_3_5_64_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbcan.2019.188319"},{"key":"e_1_3_5_65_1","unstructured":"Hon-Wah M Fitzpatrick Timothy D Anthony F et al. Solid forms comprising (ie 4e)-2-amino-N N-dipropyl-8-(4-(pyrrolidine-l-carbonyl)phenyl)-3H-benzo[b]azepine-4 carboxamide compositions thereof and uses thereof. Wo2016\/100302al. 2016."},{"key":"e_1_3_5_66_1","unstructured":"Evangelos A Gregory C Mackman Richard L et al. Toll-like receptor modulating 4 6-diamino-pyrido[3 2-d]pyrimidine compounds. Wo2016\/141092Al. 2016."},{"key":"e_1_3_5_67_1","unstructured":"Chipman Stewart D John D Radwan K et al. Alkyl chain modified imidazoquinoline TLR7\/8 agonist compounds and uses thereof. Wo2019\/040491Al. 2019."},{"key":"e_1_3_5_68_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-022-01876-6"},{"key":"e_1_3_5_69_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12935-023-02990-y"},{"key":"e_1_3_5_70_1","unstructured":"Cristiana G Coffman Robert L. Polynucleotide toll-like receptor 9 agonists for treating cancer of the lung. Us2016\/0346312al. 2016."},{"key":"e_1_3_5_71_1","unstructured":"Katz Steven C Cox Bryan F Ghosh Chandra C et al. Methods of treating immune dysfunction in liver cancer with toll-like receptor agonists. WO2023\/141599A2. 2023."},{"key":"e_1_3_5_72_1","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.16723"},{"key":"e_1_3_5_73_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1227833"},{"key":"e_1_3_5_74_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15153978"},{"key":"e_1_3_5_75_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0959-8049(22)01139-X"},{"key":"e_1_3_5_76_1","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-003521"},{"key":"e_1_3_5_77_1","unstructured":"Slingluff J Craig L Mauldin IS. Compositions and methods for treating melanoma. Wo2015\/123496al. 2015."},{"key":"e_1_3_5_78_1","volume-title":"Recent advances in immunotherapies against infectious diseases. Immunotherapy advances","author":"Ramamurthy D","year":"2021","unstructured":"Ramamurthy D, Nundalall T, Cingo S, et al. Recent advances in immunotherapies against infectious diseases. Immunotherapy advances. Oxford University Press; 2021."},{"key":"e_1_3_5_79_1","volume-title":"Cancer immunotherapy: pros, cons and beyond. Biomedicine and pharmacotherapy","author":"Tan S","year":"2020","unstructured":"Tan S, Li D, Zhu X. Cancer immunotherapy: pros, cons and beyond. Biomedicine and pharmacotherapy. Elsevier Masson SAS; 2020."},{"key":"e_1_3_5_80_1","unstructured":"Shanta B. Guanosine as an immunepotentiator mediated through toll receptors. WO2015\/167616Al. 2015."},{"key":"e_1_3_5_81_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41423-021-00726-4"},{"key":"e_1_3_5_82_1","article-title":"Immunological reagent","author":"Jackson DC","year":"2016","unstructured":"Jackson DC, Chua BYL, Sekiya T. Immunological reagent. WO2016\/037240A1. 2016.","journal-title":"WO2016\/037240A1"},{"key":"e_1_3_5_83_1","unstructured":"Christophe D Christopher S Francesca M et al. Cancer immunotherapy. Wo2021\/042171al. 2021."},{"key":"e_1_3_5_84_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.biomaterials.2022.121831"},{"key":"e_1_3_5_85_1","unstructured":"Michael B Rene W. Tumor treatment. EP2708236A1. 2014."},{"key":"e_1_3_5_86_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.actbio.2023.09.013"},{"key":"e_1_3_5_87_1","doi-asserted-by":"publisher","DOI":"10.1021\/acsami.4c04891"},{"key":"e_1_3_5_88_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-023-01674-3"},{"key":"e_1_3_5_89_1","unstructured":"Shirwan H. Adjuvant compositions with 4-1BBL. US20140199347AI. 2014."},{"key":"e_1_3_5_90_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1375767"},{"key":"e_1_3_5_91_1","unstructured":"Meulen Jan Henrik T Cuenca Carlos V P. Immunotherapy of cancer through combination of local and systemic immune stimulation. Wo2015\/123496al. 2015."},{"key":"e_1_3_5_92_1","doi-asserted-by":"publisher","DOI":"10.20892\/j.issn.2095-3941.2024.0055"},{"key":"e_1_3_5_93_1","unstructured":"Denny Nejad K Wolchok Jedd D Taha M. Methods and compositions for chemotherapy. WO2017\/024296. 2017."},{"key":"e_1_3_5_94_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-14-2538"},{"key":"e_1_3_5_95_1","unstructured":"Cluff Christopher W Hua-Xin G. Tlr4 agonists and compositions thereof and their use in the treatment of cancer. WO2017\/021792Al. 2017."},{"key":"e_1_3_5_96_1","doi-asserted-by":"publisher","DOI":"10.1038\/s42003-022-04403-8"},{"key":"e_1_3_5_97_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.coviro.2023.101330"},{"key":"e_1_3_5_98_1","unstructured":"Alfonso C Roberto D Veljko V et al. Peptide agonists of toll like receptor 5 ligand and methods of use. WO2015\/166010Al. 2015."},{"key":"e_1_3_5_99_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.gendis.2022.02.007"},{"key":"e_1_3_5_100_1","unstructured":"Andrei G Burdelya Lyudmila G. Uses of flagellin for improved chemotherapy. Wo 2015\/127227 al. 2015."},{"key":"e_1_3_5_101_1","doi-asserted-by":"publisher","DOI":"10.1038\/s43018-024-00889-9"},{"key":"e_1_3_5_102_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-023-01826-7"},{"key":"e_1_3_5_103_1","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2025.2452654"},{"key":"e_1_3_5_104_1","unstructured":"Wagner Samuel C Kim Andy J Theofilopoulos Dimitri N et al. Use of antioxidants as an adjuvant to immune stimulators to augment tumor immunity and prevent toxicity associated with oxidative stress. US20150342925. 2015 p. A1."},{"key":"e_1_3_5_105_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.chom.2018.12.006"},{"key":"e_1_3_5_106_1","unstructured":"Alex C Bernhard Hubert J Hoffman Timothy Z et al. Antibody conjugates comprising toll-like receptor agonist. Wo2017\/072662Al. 2017."},{"key":"e_1_3_5_107_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-023-01844-5"},{"key":"e_1_3_5_108_1","doi-asserted-by":"crossref","unstructured":"Kawakubo M Glahn J Tao Z et al. Fractional laser treatment boosts systemic anti-tumor immunity in combination with OX40 agonist and PD-1 blockade [Internet]. 2021. Available from: http:\/\/biorxiv.org\/lookup\/doi\/10.1101\/2021.11.29.470433","DOI":"10.1101\/2021.11.29.470433"},{"key":"e_1_3_5_109_1","unstructured":"Fisher David E Lo Jennifer A Dieter M et al. Methods for treating cancer by enhancing intratumoral immune response. WO2017\/079431Al. 2017."},{"key":"e_1_3_5_110_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41698-023-00364-1"},{"key":"e_1_3_5_111_1","unstructured":"Alex C Bernhard Hubert G Rodrigo Andreas H et al. Antibody conjugates comprising toll-like receptor agonist and combination therapies. WO2018\/198091Al. 2018."},{"key":"e_1_3_5_112_1","unstructured":"Ota Y Otsubo T. Combination drug including TLR7 agonist. WO2019\/124500A1. 2019."},{"key":"e_1_3_5_113_1","doi-asserted-by":"publisher","DOI":"10.3892\/ijo.2022.5371"},{"key":"e_1_3_5_114_1","unstructured":"Lioux T Drocourt D Vernejoul F et al. Tiraby G\u00e9rard Perouzel Eric. Conjugated TLR7 and\/or TLR8 and TLR2 polycationic agonists. EP2769738A1. 2014."},{"key":"e_1_3_5_115_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers17020194"},{"key":"e_1_3_5_116_1","doi-asserted-by":"publisher","DOI":"10.1186\/s40364-022-00436-7"},{"key":"e_1_3_5_117_1","unstructured":"David S Kelly F. TLR-agonist-conjugated antibody recruiting molecules (TLR-ARMS). Us2015\/0110742a l. 2015."},{"key":"e_1_3_5_118_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrc2051"},{"key":"e_1_3_5_119_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-022-00947-7"},{"key":"e_1_3_5_120_1","unstructured":"Lixin L. A novel complex comprising a cell penetrating peptide a cargo and a TLR peptide agonist for treatment of colorectal cancer. Wo2016\/004875al. 2016."},{"key":"e_1_3_5_121_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1228486"},{"key":"e_1_3_5_122_1","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines11020277"},{"key":"e_1_3_5_123_1","unstructured":"Saul K Marlene H Anand Neel K et al. Immunotherapeutic tumor treatment method. Wo2018\/204528Al. 2018."},{"key":"e_1_3_5_124_1","unstructured":"Svetlana H. Pharmaceutical combination products comprising a histone deacetylase (HDAC) inhibitor and a TLR7 agonist and\/or TLR8 agonist for the treatment of cancer. Wo2019\/197682al. 2019."},{"key":"e_1_3_5_125_1","unstructured":"David D-C. Pharmaceutical compositions comprising an inhibitor of a histon-deacetylase (HDACi) and an agonist of toll-like-receptor 7 and\/or 8 (TLR7 and\/or TLR8) and their use in the treatment of cancer. Wo2021\/099402al. 2021."},{"key":"e_1_3_5_126_1","unstructured":"Low Philip S John Victor N Fenghua Z. Compounds compositions and methods for the treatment of fibrotic diseases and cancer. WO2022\/011043A2. 2022."},{"key":"e_1_3_5_127_1","unstructured":"Sudhakar Reddy C Ruth Ingeborg Johanna S Stina Lisa U et al. Combination therapies using TLR7\/8 agonist. Wo2023\/079428al. 2023."},{"key":"e_1_3_5_128_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-16-1934"},{"key":"e_1_3_5_129_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-16-1453"},{"key":"e_1_3_5_130_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14153575"},{"key":"e_1_3_5_131_1","unstructured":"Dietsch Gregory N. Use of TLR8 agonists to treat cancer. Wo2017\/079283Al. 2017."},{"key":"e_1_3_5_132_1","unstructured":"Valerie O Baum Peter R Thompson Peter A. Combination therapy with immune stimulatory conjugates. Wo2021\/067644al. 2021."},{"key":"e_1_3_5_133_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.imlet.2007.11.014"},{"key":"e_1_3_5_134_1","doi-asserted-by":"publisher","DOI":"10.1186\/2051-1426-2-12"},{"key":"e_1_3_5_135_1","doi-asserted-by":"publisher","DOI":"10.1177\/1753425918771178"},{"key":"e_1_3_5_136_1","unstructured":"Klinman Dennis M Gan Z Akos J. TLR-9 agonist with TLR-7 and\/or TLR-8 agonist for treating tumors. WO2014201245A1. 2014."},{"key":"e_1_3_5_137_1","doi-asserted-by":"publisher","DOI":"10.1002\/imed.1025"},{"key":"e_1_3_5_138_1","unstructured":"Jun Kim Y Pardoll DM Fu J. Cancer immunotherapy. US20140341978AI. 2014."},{"key":"e_1_3_5_139_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2017.01.017"},{"key":"e_1_3_5_140_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.coph.2011.03.004"},{"key":"e_1_3_5_141_1","unstructured":"Adriana B Eugene M. Anti-tumor compositions and uses thereof. US20150037374A1. 2015."},{"key":"e_1_3_5_142_1","unstructured":"Ragupathy M Nicodemus Christopher F. Tumor antigen specific antibodies and TLR3 stimulation to enhance the performance of checkpoint interference therapy of cancer. Wo2016\/019472Al. 2016."},{"key":"e_1_3_5_143_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2014.10.006"},{"key":"e_1_3_5_144_1","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.868695"},{"key":"e_1_3_5_145_1","unstructured":"Weissman Irving L Mingye F Jens-Peter V. Macrophages eat cancer cells using their own calreticulin as a guide. WO2016\/118754Al. 2016."},{"key":"e_1_3_5_146_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2019.12.011"},{"key":"e_1_3_5_147_1","doi-asserted-by":"publisher","DOI":"10.1111\/cas.12861"},{"key":"e_1_3_5_148_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13092232"},{"key":"e_1_3_5_149_1","unstructured":"Kutok Jeffery L. Combination therapy. Wo2017\/223422al. 2017."},{"key":"e_1_3_5_150_1","unstructured":"Lee Ventola C. Cancer immunotherapy part 3: challenges and future trends. 2017."},{"key":"e_1_3_5_151_1","article-title":"Combined TLRS modulators with anti 0X40 antibodies","author":"John FC","year":"2017","unstructured":"John FC, Niranjan Y. Combined TLRS modulators with anti 0X40 antibodies. WO2017\/021912Al. 2017.","journal-title":"WO2017\/021912Al"},{"key":"e_1_3_5_152_1","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines12092158"},{"key":"e_1_3_5_153_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.semcancer.2015.03.004"},{"key":"e_1_3_5_154_1","unstructured":"Tomoya M Shun D Koji T. Medicine. Wo 2018\/070069 [Internet]. 2016. Available from: www.opic.ic.gc.ca"},{"key":"e_1_3_5_155_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-022-01247-x"},{"key":"e_1_3_5_156_1","unstructured":"McNeel Douglas G Zahm Christopher D. TLR agonists for reducing activation-induced PD-I expression on T cells and methods of use. Us2018\/0169224al. 2018."},{"key":"e_1_3_5_157_1","unstructured":"Oppenheim JJ Yang D Han Z et al. Therapeutic antitumor combination of a TLR4 ligand with other treatments. WO2018004747A1. 2018."},{"key":"e_1_3_5_158_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2019.04.003"},{"key":"e_1_3_5_159_1","unstructured":"Madiha D Elodie B. Fusion comprising a cell penetrating peptide a multi epitope and a TLR peptide agonist for treatment of cancer. WO2018\/055060Al. 2018."},{"key":"e_1_3_5_160_1","unstructured":"Fabienne A Feriel H-R Emmanuel V et al. Methods and compositions for treating precancerous lesions or cancer comprising TLR\/TLR or TLR\/CLR agonists. Wo2018\/060513al. 2018."},{"key":"e_1_3_5_161_1","unstructured":"Tianxin W. Methods and agents to treat tumor cells and cancer. US 2019\/0160174Al. 2019."},{"key":"e_1_3_5_162_1","unstructured":"Hakim G Strauss-Ayali D Friedman A et al. Immunomodulating treatments of body cavities. Us2019\/0201334al. 2019."},{"key":"e_1_3_5_163_1","unstructured":"Jonathan Z Anand Neel K Haiying C et al. Immunotherapeutic tumor treatment method. Wo 2019\/036031a2. 2019."},{"key":"e_1_3_5_164_1","unstructured":"Keith B. Oncolytic cancer immunotherapies and methods of use. Wo2019\/074842Al. 2019."},{"key":"e_1_3_5_165_1","unstructured":"Matthew V Hung-Sen L Amrik B et al. Tumor microenvironment-activated drug-binder conjugated and uses related thereto. WO2019\/236567A2. 2019."},{"key":"e_1_3_5_166_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-021-00524-z"},{"key":"e_1_3_5_167_1","unstructured":"Gantier Michael Paul Marie. Oligonucleotides. Wo2022\/213153Al. 2022."},{"key":"e_1_3_5_168_1","unstructured":"Jung Soo S Seungwoo C Yunxuan X. Use of a conjugate of anti-CD47 antibody and toll-like receptor agonist. Wo2024\/006538al. 2024."},{"key":"e_1_3_5_169_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-024-02002-z"},{"key":"e_1_3_5_170_1","doi-asserted-by":"publisher","DOI":"10.1021\/acscentsci.8b00823"},{"key":"e_1_3_5_171_1","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics11090441"},{"key":"e_1_3_5_172_1","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines10111946"},{"key":"e_1_3_5_173_1","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines12121335"},{"key":"e_1_3_5_174_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2008.04.022"},{"key":"e_1_3_5_175_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-10-1993"},{"key":"e_1_3_5_176_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2014.11.009"},{"key":"e_1_3_5_177_1","unstructured":"Andrei VG. Viral vector encoding a toll-like receptor and encoding a toll-like receptor agonist. US009205095B2. 2015."},{"key":"e_1_3_5_178_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2024.113089"},{"key":"e_1_3_5_179_1","unstructured":"Gindy Marian E Casimiro Danilo R Kaufman David R et al. Combination therapy of anti-IL-10 antibody and compositions comprising lipid nanoparticles and TLR9 agonist CpG oligonucleotides. WO2017\/192470Al. 2017."},{"key":"e_1_3_5_180_1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21834"},{"key":"e_1_3_5_181_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-024-01055-z"},{"key":"e_1_3_5_182_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx683"},{"key":"e_1_3_5_183_1","unstructured":"Cristiana G Edwina N Milley Robert J et al. Intratumoral administration of particles containing a toll-like receptor 9 agonist and a tumor antigen for treating cancer. Wo2017\/181128al. 2017."},{"key":"e_1_3_5_184_1","unstructured":"Tianxin W. Reagents and methods for cancer treatment using magnetic particle. Us2018\/0296850al. 2018."},{"key":"e_1_3_5_185_1","doi-asserted-by":"publisher","DOI":"10.21037\/tlcr.2016.06.07"},{"key":"e_1_3_5_186_1","unstructured":"Desimone Joseph M Jillian P Chin-Tan K et al. Toll-like receptor agonist modified particles and their use in lung cancer. WO2018\/207153Al. 2018."},{"key":"e_1_3_5_187_1","unstructured":"Thomas Lars A Jonas Rosager H Martin Kisha K. TLR7\/8 agonists and liposome compositions. Wo2020\/023680al. 2020."},{"key":"e_1_3_5_188_1","unstructured":"Jong Jondavid D Stephanie D-O Karl Michael K et al. Compounds and compositions for potentiation of TLR agonists. WO2020\/037433Al. 2020."},{"key":"e_1_3_5_189_1","unstructured":"David S Dhruba B Hay Bruce A et al. Formulated and\/or co-formulated liposome compositions containing toll-like receptor (TLR) agonist prodrugs useful in the treatment of cancer and methods thereof. Wo2021\/126281Al. 2021."},{"key":"e_1_3_5_190_1","unstructured":"Mirkin Chad A Ziyin H Lisa C et al. Synergistic immunostimulation through the dual activation of TLR3\/9 with spherical nucleic acids. Us2022\/0370490al. 2022."},{"key":"e_1_3_5_191_1","unstructured":"Qian Y Davis Mark M. Immunostimulatory toll-like receptor agonist-nanoparticle for cancer immunotherapy. Wo2022\/226032al. 2022."},{"key":"e_1_3_5_192_1","unstructured":"Nicolas C Patrice D Roland V et al. Immunological adjuvant formulations comprising TLR4 agonist E6020. Wo2023\/056089Al. 2023."},{"key":"e_1_3_5_193_1","unstructured":"Chun-Tien K Zhongkun Z Robert L. Immunotherapies for the treatment of cancer. Wo2023\/070132al. 2023."},{"key":"e_1_3_5_194_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15112912"},{"key":"e_1_3_5_195_1","unstructured":"Nel Andre E Lijia L Sabomi C. A drug nanocarrier system to deliver a combination of TLR agonists and\/or a lipoxin plus immunogenic cell death inducing chemotherapeutic agents for cancer immunotherapy. WO2023\/172300Al. 2023."},{"key":"e_1_3_5_196_1","unstructured":"Appel Eric A Ben O Julie B. TLR agonists comprising saponin nanoparticle vaccine adjuvants to improve immunomodulation. WO2023\/235592A2. 2023."},{"key":"e_1_3_5_197_1","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2023.1249718"},{"key":"e_1_3_5_198_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-021-00574-3"},{"key":"e_1_3_5_199_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2014.12.082"},{"key":"e_1_3_5_200_1","unstructured":"Percy K Mathias H Ulrike P et al. Vaccination strategy. Wo 2014\/128305 Al. 2014."},{"key":"e_1_3_5_201_1","doi-asserted-by":"publisher","DOI":"10.1128\/IAI.00911-18"},{"key":"e_1_3_5_202_1","unstructured":"Hang Y Kui C. 2-(4-aryl-17\/-imidazol-l-yl)aniline compounds. Wo2015\/171951Al. 2015."},{"key":"e_1_3_5_203_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-024-01856-7"},{"key":"e_1_3_5_204_1","unstructured":"Gao D Wang L Yanyuan C et al. Purine-scaffold TLR7 ligands and conjugate thereof. Wo2017\/197624Al. 2017."},{"key":"e_1_3_5_205_1","unstructured":"Dowling David J Ofer L Francesco B et al. Use of toll-like receptor 2 (TLR-2) agonist for modulating human immune response. Wo2020\/023872al. 2020."},{"key":"e_1_3_5_206_1","unstructured":"Hubbell Jeffrey A Wilson David S Marchell Tiffany M et al. Methods and compositions for treating cancer with cancer-targeted adjuvants. Wo2020\/247973Al. 2020."},{"key":"e_1_3_5_207_1","unstructured":"Tarby Christine M Qiang C Gaval Ashvinikumar V et al. C3-substituted 1H-pyrazolo[4.3-d]pyrivlidine compounds as toll-like receptor 7 (TLR7) agonists. Wo2021\/154667al. 2021."},{"key":"e_1_3_5_208_1","unstructured":"Tianxin W. Methods agents and compositions as in situ vaccine for cancer cell and tumor treatment. Us2022\/0040310al. 2022."},{"key":"e_1_3_5_209_1","unstructured":"Kyle S Sam B Katrina G. Combination therapy tumour cell vaccine. Wo2022\/241560al. 2022."},{"key":"e_1_3_5_210_1","article-title":"TLR3 and TLR9 agonists as vaccine adjuvants for anti-cancer DNA vaccines","author":"McNeel D","unstructured":"McNeel D, Jeon D. TLR3 and TLR9 agonists as vaccine adjuvants for anti-cancer DNA vaccines. US2023\/0201341Al. 2023.","journal-title":"US2023\/0201341Al. 2023"},{"key":"e_1_3_5_211_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-011-0984-8"},{"key":"e_1_3_5_212_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12123824"},{"key":"e_1_3_5_213_1","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines10071590"},{"key":"e_1_3_5_214_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1200598"},{"key":"e_1_3_5_215_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.tranon.2023.101851"},{"key":"e_1_3_5_216_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2017.05.006"},{"key":"e_1_3_5_217_1","unstructured":"Daqing W Wayne J Sudhir A. Treatment of cancer using TLR9 agonist with checkpoint inhibitors. Wo2016\/057898Al. 2016."},{"key":"e_1_3_5_218_1","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-019-0724-8"},{"key":"e_1_3_5_219_1","unstructured":"Zachary Aaron C Shannon Renae M. Safety and pharmacodynamic activity of a toll-like receptor 7\/8 agonist background. Wo2018\/132539Al. 2018."},{"key":"e_1_3_5_220_1","unstructured":"Quay Steven C. In situ methods of inducing of immune response. Wo2019\/177991al. 2019."},{"key":"e_1_3_5_221_1","unstructured":"David B Zuniga Luis R Juha P-N Lars HAD et al. Sustained local drug levels for innate immune agonists. Wo2020\/141222al. 2020."},{"key":"e_1_3_5_222_1","unstructured":"Rosen David B Luis Z Juha P-N et al. Minimization of systemic inflammation. WO2020\/141225AI. 2020."},{"key":"e_1_3_5_223_1","unstructured":"Breinholt Vibeke M Stina S. Novel cancer treatments with TLR7\/8 agonists. WO2023\/110727A2. 2023."},{"key":"e_1_3_5_224_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2015.03.006"},{"key":"e_1_3_5_225_1","doi-asserted-by":"publisher","DOI":"10.7774\/cevr.2013.2.2.128"},{"key":"e_1_3_5_226_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2020.104746"},{"key":"e_1_3_5_227_1","doi-asserted-by":"publisher","DOI":"10.1002\/adhm.202404335"},{"key":"e_1_3_5_228_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14071732"},{"key":"e_1_3_5_229_1","unstructured":"Madiha D Elodie B. A novel complex comprising a cell penetrating peptide a cargo and a TLR peptide agonist for treatment of colorectal cancer. Wo2016\/146262Al. 2016."},{"key":"e_1_3_5_230_1","unstructured":"Madiha D Elodie B. Combination of an immune checkpoint modulator and a complex comprising a cell penetrating peptide a cargo and a TLR peptide agonist for use in medicine. Wo2016\/146261al. 2016."},{"key":"e_1_3_5_231_1","unstructured":"Lawrence Nathan T Emmanuel O. TLR7 and TLR8 agonists for the treatment of cancer and\/or infectious diseases. Wo2022\/187809Al. 2022."},{"key":"e_1_3_5_232_1","unstructured":"Sung-Ju M Brian L Mingchao K et al. \u0391ntibody-TLR agonist conjugates methods and uses thereof. Wo2022\/040596al Moon Sung-ju Leon Brian Kang Mingchao Knudsen Nickolas Sakamuri Sukumar Tian Feng. 2022."},{"key":"e_1_3_5_233_1","unstructured":"Takumi K Takuji S Tatsuya K et al. Conjugates binding phosphatidylserine and toll-like receptors. Wo2023\/126885al. 2023."},{"key":"e_1_3_5_234_1","doi-asserted-by":"publisher","DOI":"10.3390\/gels7040224"},{"key":"e_1_3_5_235_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-024-05102-0"},{"key":"e_1_3_5_236_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.chemrev.0c01177"},{"key":"e_1_3_5_237_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpha.2024.100964"},{"key":"e_1_3_5_238_1","unstructured":"Gil H Dalit S-A Astar F et al. Immunomodulating treatments of body cavities. Wo2018\/078620al. 2018."},{"key":"e_1_3_5_239_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-05-432393"},{"key":"e_1_3_5_240_1","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.7928"},{"key":"e_1_3_5_241_1","unstructured":"Katz Steven C Cox Bryan F David Benjamin J. Cancer therapy using toll-like receptor agonists. Wo2022\/066670al. 2022."},{"key":"e_1_3_5_242_1","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202301339"},{"key":"e_1_3_5_243_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-10-3262"},{"key":"e_1_3_5_244_1","unstructured":"Yanliang Z Qingling H Zhongyuan T et al. Modified immune cells expressing TLR receptors. Wo2023\/020558al. 2023."}],"container-title":["Expert Opinion on Therapeutic Patents"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/13543776.2025.2556819","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T03:57:59Z","timestamp":1762142279000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/13543776.2025.2556819"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,18]]},"references-count":242,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,11,2]]}},"alternative-id":["10.1080\/13543776.2025.2556819"],"URL":"https:\/\/doi.org\/10.1080\/13543776.2025.2556819","relation":{},"ISSN":["1354-3776","1744-7674"],"issn-type":[{"value":"1354-3776","type":"print"},{"value":"1744-7674","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,18]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ietp20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ietp20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2025-04-02","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-09-01","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-09-18","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}